Prostate Cancer | Specialty

Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer

December 1st 2016

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

November 29th 2016

​Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Dr. Rathkopf on Investigative Agents in Prostate Cancer

November 28th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.

Dr. Sandler on Chemotherapy Combination Regimens in Prostate Cancer

November 28th 2016

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

November 23rd 2016

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

New Imaging Strategies for Prostate Cancer Explored

November 23rd 2016

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

Expert Discusses the Future of Circulating Biomarkers in Prostate Cancer

November 23rd 2016

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

Researcher Hopes Liquid Biopsies Will Make Mark in Prostate Cancer

November 21st 2016

How oncologists can translate their increased understanding of the biology of prostate cancer into clinical practice is a question being raised currently in the field, explains Howard I. Scher, MD, adding, that the emergence of liquid biopsies could possibly be one way to tackle the issue.

Biomarkers, Combo Regimens Key to Mitigating AR-Resistance in mCRPC

November 21st 2016

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

November 21st 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

Dreicer Discusses Optimizing Treatment in mCRPC

November 19th 2016

As oncologists await the next major treatment advances in metastatic castration-resistant prostate cancer (mCRPC), the key in the interim is to optimize the available therapies, says Robert Dreicer, MD.

Dr. Stein on Circulating Biomarkers in Prostate Cancer

November 19th 2016

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.

Dr. Morris on Novel Approaches With Radium-223 in mCRPC

November 18th 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

November 18th 2016

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Scher on Predicting Sensitivity to Treatment for mCRPC

November 18th 2016

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Kantoff Highlights Continued Role for Docetaxel in Metastatic Prostate Cancer

November 16th 2016

While immunotherapy continues to make headway in various malignancies, the chemotherapy docetaxel maintains a key role in the treatment of patients with metastatic prostate cancer.

Newly Identified Molecular Subtypes Could Guide Treatment Decisions in Prostate Cancer

November 16th 2016

Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.

Dr. Rathkopf on Mitigating AR-Resistance in Prostate Cancer

November 15th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses mitigating androgen receptor (AR)-resistance in patients with prostate cancer.

Dr. Bryan Mehlhaff on Advances in mCRPC

November 12th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).